UFP Technologies 3Q 2026: Revenue $172.43M, EPS $2.64 — 10-Q Summary
UFP Technologies reported 3Q 2026 revenue of $172.43M, up 11.6% YoY, with net income of $20.62M, a 25.8% increase. EPS rose to $2.64. Growth was driven by medical segments, with organic sales up 11.1% and gross margin improving to 29.4%. The company acquired CI Medical for $6.9M.
How this was made
The 30-second read
Why it matters
The earnings beat and margin expansion provide a fresh catalyst for the stock, likely prompting short‑term buying.
Market read
First‑time disclosure of Q3 results offers actionable insight for traders targeting small‑cap healthcare stocks.
What to watch
Integration risk from the recent CI Medical acquisition and potential supply‑chain constraints.
Background
UFP Technologies filed its Q3 2026 Form 10‑Q, summarizing financial performance and a recent acquisition.
Ticker impact
UFP Technologies reported Q3 2026 net sales of $172.43M and diluted EPS of $2.64, up 11.6% and 25.8% YoY respectively.
upward pressure as the market prices in the earnings beat and margin improvement
Revenue and EPS both rose significantly year‑over‑year, and gross margin expanded, indicating better pricing and cost control.
Market effects
Positive earnings may lift sentiment in the medical‑device and healthcare‑services sector.
U.S. small‑cap healthcare stocks could see modest buying interest.
Limited; impact confined mainly to U.S. investors focused on niche medical‑device players.
Counterpoint
The modest absolute revenue size and competitive pressures could limit upside despite the beat.
Key entities
- CompanyUFP Technologies Inc.
U.S. medical‑device manufacturer (ticker UFPT).
